Citadel Advisors
MOR

Citadel Advisors’s MorphoSys AG American Depositary Shares MOR Stock Holding History

Citadel Advisors’s Portfolio MOR Stock Details MOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,300
Closed -$151K – 15628
2024
Q2 		$151K Sell
8,300
-9,200
-53% -$167K ﹤0.01% 10343
2024
Q1 		$317K Sell
17,500
-4,500
-20% -$66.5K ﹤0.01% 9334
2023
Q4 		$218K Buy
22,000
+18,300
+495% +$134K ﹤0.01% 9776
2023
Q3 		$24.9K Buy
3,700
+500
+16% +$3.85K ﹤0.01% 12439
2023
Q2 		$23.9K Buy
+3,200
New +$19.5K ﹤0.01% 12578

Other funds holding MOR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's MOR Position: Q2 2024 in Review

Citadel Advisors sold out of MorphoSys AG American Depositary Shares (MOR) in Q2 2024, closing a stake of 3,594 shares — an estimated $65.3K sold.

Citadel Advisors first reported a position in MOR in Q2 2018 and held it in 16 quarters. The position peaked at $3.71M in Q2 2020. 26 funds tracked by Wall St. Rank hold MOR as of Q2 2024.

  • Citadel Advisors reported no remaining MorphoSys AG American Depositary Shares position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 3,594 MorphoSys AG American Depositary Shares shares in Q2 2024, an estimated $65.3K.
  • Citadel Advisors first reported a position in MorphoSys AG American Depositary Shares in Q2 2018 and held it in 16 quarters.
  • Citadel Advisors's MorphoSys AG American Depositary Shares position peaked at $3.71M in Q2 2020.
  • 26 funds tracked by Wall St. Rank held MorphoSys AG American Depositary Shares as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.